Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese drug maker Takeda Pharmaceutical Company has announced that TAK-491, its investigational compound for the treatment of hypertension, has entered the Phase III clinical stage in the US and Europe.
Subscribe to our email newsletter
TAK-491 is an angiotensin receptor blocker (ARB) discovered by Takeda that lowers blood pressure. Takeda said that TAK-491 is expected to show stronger anti-hypertensive action, and also to have superior profile in improving the insulin resistance and decreasing proteinuria, as compared to existing ARBs on the market.
“We are pleased with the progress of TAK-491’s development stage into Phase III as this compound is expected to succeed our current mainstay product, candesartan, [sold under the brand Blopress] an ARB,” said Masaomi Miyamoto, general manager of Takeda’s pharmaceutical development division.
Dr Miyamoto went on to say that Takeda believes that TAK-475 will enhance the company’s most important therapeutic areas of metabolic diseases, including hypertension, diabetes and hypercholesterolemia among others.